explore -WSS

explore

author：leisure time 2025-09-28 06:09:00 - browse：419

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Editas, Vertex strike deal on CRISPR

focus

WSS

Stoke drug shows lower activity against childhood epilepsy

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Marc Tessier

In Spain, a hospital brews its own CAR

Medicare drug price negotiation hasn't dried up venture capital

Biden to sign 'historic' executive order on how US military handles sexual assault cases

focus

explore

hotspot

23andMe had bad news about my health. I wish a person had delivered it

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Supreme Court strikes down use of affirmative action

David Ricks of Eli Lilly: best biopharma CEO of 2023

Wildfire smoke exposes gaps in outdoor worker protections

Ending health disparities requires full federal government, panel says

Novavax promises a turnaround & Lilly roils the obesity market

Can sheer will power keep patients alive in their dying hours?

Cancer drug shortages should be causing more outrage

SEC charges former device maker CEO with $41 million fraud

entertainment

Violet CEO on training clinicians to promote more inclusive care

SNAP should offer more nutrition education

Biden to sign 'historic' executive order on how US military handles sexual assault cases

'Hero' Louisville officer shot in head at mass shooting discharged over 3 months later

Medicare Advantage beneficiaries sue Humana over algorithm use

Medicare drug price negotiation hasn't dried up venture capital

entertainment

focus

hotspot

focus